French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment similar to Novartis's recently approved Kymriah, has been forced to suspend testing following a patient death. More »
Cellectis has won U.S. regulatory approval to run an early clinical trial using its gene edited cell therapy product UCART123 for blood cancers, boosting the French biotech firm’s ambitions in the hot area of cancer research. More »
We use cookies!
By using this site you agree to the use of cookies, more info.